Cargando…

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

INTRODUCTION: The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Charleux, Thomas, Vendrely, Véronique, Huchet, Aymeri, Trouette, Renaud, Ferrière, Amandine, Tabarin, Antoine, Jecko, Vincent, Loiseau, Hugues, Dupin, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559766/
https://www.ncbi.nlm.nih.gov/pubmed/36229880
http://dx.doi.org/10.1186/s13014-022-02133-z
_version_ 1784807701344157696
author Charleux, Thomas
Vendrely, Véronique
Huchet, Aymeri
Trouette, Renaud
Ferrière, Amandine
Tabarin, Antoine
Jecko, Vincent
Loiseau, Hugues
Dupin, Charles
author_facet Charleux, Thomas
Vendrely, Véronique
Huchet, Aymeri
Trouette, Renaud
Ferrière, Amandine
Tabarin, Antoine
Jecko, Vincent
Loiseau, Hugues
Dupin, Charles
author_sort Charleux, Thomas
collection PubMed
description INTRODUCTION: The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose of this study was to evaluate the therapeutic outcome for each option. METHODS: The records of 256 patients followed with NFPA between 2007 and 2018 were retrospectively reviewed. Mean age at initial surgery was 55 years [18–86]. Post-operative MRI found a residual tumor in 87% of patients. Mean follow-up was 12.1 years [0.8–42.7]. RESULTS: After initial surgery, 40 patients had adjuvant radiotherapy. At 5, 10 and 15 years progression-free survival (PFS) was significantly different after surgery alone (77%, 58% and 40%) compared to surgery and adjuvant radiotherapy (84%, 78% and 78%) (HR = 0.24 [0–0.53] p < 0.0005). Overall, after first, second or third surgical operation, 69 patients had adjuvant radiotherapy and 41 salvage radiotherapy. Five-year PFS was similar for adjuvant (90%) and salvage radiotherapy (97%) (p = 0.62). After a second surgical operation, 62% and 71% of patients were irradiated after 2 and 5 years respectively. The risk of corticotropic and thyrotropic deficiency rates were 38% and 59% after second or third surgical operation and 40% and 73% after radiotherapy. Brain tumors occurred in 4 patients: 1 meningioma present at initial surgery, and after radiotherapy, 1 neurinoma which appeared at 5 years, 1 glioblastoma at 13 years and 1 meningioma at 20 years. CONCLUSION: Among patients treated by surgery for NFPA, a “wait-and-see” attitude should be an option since adjuvant radiotherapy is not superior to salvage radiotherapy. However, in case of recurrence or progression, the authors recommended delivery of salvage radiotherapy to avoid a second surgical operation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-022-02133-z.
format Online
Article
Text
id pubmed-9559766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95597662022-10-14 Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery? Charleux, Thomas Vendrely, Véronique Huchet, Aymeri Trouette, Renaud Ferrière, Amandine Tabarin, Antoine Jecko, Vincent Loiseau, Hugues Dupin, Charles Radiat Oncol Research INTRODUCTION: The first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose of this study was to evaluate the therapeutic outcome for each option. METHODS: The records of 256 patients followed with NFPA between 2007 and 2018 were retrospectively reviewed. Mean age at initial surgery was 55 years [18–86]. Post-operative MRI found a residual tumor in 87% of patients. Mean follow-up was 12.1 years [0.8–42.7]. RESULTS: After initial surgery, 40 patients had adjuvant radiotherapy. At 5, 10 and 15 years progression-free survival (PFS) was significantly different after surgery alone (77%, 58% and 40%) compared to surgery and adjuvant radiotherapy (84%, 78% and 78%) (HR = 0.24 [0–0.53] p < 0.0005). Overall, after first, second or third surgical operation, 69 patients had adjuvant radiotherapy and 41 salvage radiotherapy. Five-year PFS was similar for adjuvant (90%) and salvage radiotherapy (97%) (p = 0.62). After a second surgical operation, 62% and 71% of patients were irradiated after 2 and 5 years respectively. The risk of corticotropic and thyrotropic deficiency rates were 38% and 59% after second or third surgical operation and 40% and 73% after radiotherapy. Brain tumors occurred in 4 patients: 1 meningioma present at initial surgery, and after radiotherapy, 1 neurinoma which appeared at 5 years, 1 glioblastoma at 13 years and 1 meningioma at 20 years. CONCLUSION: Among patients treated by surgery for NFPA, a “wait-and-see” attitude should be an option since adjuvant radiotherapy is not superior to salvage radiotherapy. However, in case of recurrence or progression, the authors recommended delivery of salvage radiotherapy to avoid a second surgical operation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-022-02133-z. BioMed Central 2022-10-13 /pmc/articles/PMC9559766/ /pubmed/36229880 http://dx.doi.org/10.1186/s13014-022-02133-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Charleux, Thomas
Vendrely, Véronique
Huchet, Aymeri
Trouette, Renaud
Ferrière, Amandine
Tabarin, Antoine
Jecko, Vincent
Loiseau, Hugues
Dupin, Charles
Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title_full Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title_fullStr Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title_full_unstemmed Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title_short Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
title_sort management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559766/
https://www.ncbi.nlm.nih.gov/pubmed/36229880
http://dx.doi.org/10.1186/s13014-022-02133-z
work_keys_str_mv AT charleuxthomas managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT vendrelyveronique managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT huchetaymeri managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT trouetterenaud managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT ferriereamandine managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT tabarinantoine managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT jeckovincent managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT loiseauhugues managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery
AT dupincharles managementafterinitialsurgeryofnonfunctioningpituitaryadenomasurveillanceradiotherapyorsurgery